Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Identifieur interne : 000B85 ( Ncbi/Merge ); précédent : 000B84; suivant : 000B86Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Auteurs : Santiago Perez Lloret [France] ; Olivier RascolSource :
- Expert opinion on pharmacotherapy [ 1744-7666 ] ; 2010.
English descriptors
- KwdEn :
- Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (pharmacokinetics), Antiparkinson Agents (pharmacology), Benzothiazoles (administration & dosage), Benzothiazoles (adverse effects), Benzothiazoles (pharmacokinetics), Benzothiazoles (pharmacology), Delayed-Action Preparations, Humans, Male, Parkinson Disease (drug therapy).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Benzothiazoles.
- chemical , adverse effects : Antiparkinson Agents, Benzothiazoles.
- chemical , pharmacokinetics : Antiparkinson Agents, Benzothiazoles.
- chemical , pharmacology : Antiparkinson Agents, Benzothiazoles.
- chemical : Delayed-Action Preparations.
- drug therapy : Parkinson Disease.
- Humans, Male.
Abstract
Immediate-release pramipexole (P-IR) is indicated three times daily for the symptomatic treatment of early and advanced Parkinson's disease (PD). An extended-release formulation of pramipexole (P-ER) has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation.
DOI: 10.1517/14656566.2010.510515
PubMed: 20670197
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A61
- to stream PubMed, to step Curation: 000A21
- to stream PubMed, to step Checkpoint: 000A21
Links to Exploration step
pubmed:20670197Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez Lloret">Santiago Perez Lloret</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20670197</idno><idno type="pmid">20670197</idno><idno type="doi">10.1517/14656566.2010.510515</idno><idno type="wicri:Area/PubMed/Corpus">000A61</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A61</idno><idno type="wicri:Area/PubMed/Curation">000A21</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A21</idno><idno type="wicri:Area/PubMed/Checkpoint">000A21</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A21</idno><idno type="wicri:Area/Ncbi/Merge">000B85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez Lloret">Santiago Perez Lloret</name><affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="eISSN">1744-7666</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Antiparkinson Agents (pharmacology)</term><term>Benzothiazoles (administration & dosage)</term><term>Benzothiazoles (adverse effects)</term><term>Benzothiazoles (pharmacokinetics)</term><term>Benzothiazoles (pharmacology)</term><term>Delayed-Action Preparations</term><term>Humans</term><term>Male</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Immediate-release pramipexole (P-IR) is indicated three times daily for the symptomatic treatment of early and advanced Parkinson's disease (PD). An extended-release formulation of pramipexole (P-ER) has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20670197</PMID><DateCreated><Year>2010</Year><Month>08</Month><Day>16</Day></DateCreated><DateCompleted><Year>2011</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2012</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>13</Issue><PubDate><Year>2010</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>2221-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14656566.2010.510515</ELocationID><Abstract><AbstractText Label="IMPORTANCE OF THE FIELD" NlmCategory="BACKGROUND">Immediate-release pramipexole (P-IR) is indicated three times daily for the symptomatic treatment of early and advanced Parkinson's disease (PD). An extended-release formulation of pramipexole (P-ER) has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation.</AbstractText><AbstractText Label="AREAS COVERED IN THIS REVIEW" NlmCategory="METHODS">This review summarizes clinical pharmacology and pharmacokinetics of P-ER for the treatment of early and advanced PD. The advantages and disadvantages of the strategies available at present for achieving continuous dopaminergic stimulation in the treatment of PD are discussed first. The pharmacological properties are then summarized. Finally, the clinical pharmacology and pharmacokinetics of P-ER are described.</AbstractText><AbstractText Label="WHAT THE READER WILL GAIN" NlmCategory="RESULTS">The reader will gain knowledge of the development of P-ER, its current place in the pharmacotherapy of PD, and future directions.</AbstractText><AbstractText Label="TAKE HOME MESSAGE" NlmCategory="CONCLUSIONS">P-ER has been shown to be efficacious in early and advanced PD and it has the same clinical profile when administered once daily as P-IR administered three times daily. An overnight switching of P-IR to dose-equivalent P-ER is successful in 80% of patients with early PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez Lloret</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, University of Toulouse, Faculty of Medicine, 37 Allées Jules Guesde, 31000 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>83619PEU5T</RegistryNumber><NameOfSubstance UI="C061333">pramipexole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20670197</ArticleId><ArticleId IdType="doi">10.1517/14656566.2010.510515</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez Lloret">Santiago Perez Lloret</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000B85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:20670197
|texte= Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:20670197" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |